Aileron-logo.png
Aileron Therapeutics to Present at Upcoming Investor Conferences
04 janv. 2022 08h45 HE | Aileron Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron-logo.png
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
20 déc. 2021 10h56 HE | Aileron Therapeutics, Inc.
BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a...
Aileron-logo.png
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
12 nov. 2021 07h50 HE | Aileron Therapeutics, Inc.
Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned...
Aileron-logo.png
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
07 oct. 2021 09h22 HE | Aileron Therapeutics, Inc.
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s...
Aileron-logo.png
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
30 sept. 2021 16h30 HE | Aileron Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron-logo.png
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
16 sept. 2021 08h15 HE | Aileron Therapeutics, Inc.
Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and...
Aileron-logo.png
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
10 sept. 2021 08h30 HE | Aileron Therapeutics, Inc.
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic...
Aileron-logo.png
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
07 sept. 2021 16h05 HE | Aileron Therapeutics, Inc.
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron-logo.png
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
27 août 2021 07h45 HE | Aileron Therapeutics, Inc.
Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal...
Aileron-logo.png
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
11 août 2021 16h20 HE | Aileron Therapeutics, Inc.
Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end...